Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
This volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, ma
- PDF / 6,898,143 Bytes
- 202 Pages / 439.42 x 683.15 pts Page_size
- 9 Downloads / 239 Views
Emmanuel Donnadieu Editor
Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
Resistance to Targeted Anti-Cancer Therapeutics
Series Editor Benjamin Bonavida
More information about this series at http://www.springer.com/series/11727
Emmanuel Donnadieu Editor
Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
Editor Emmanuel Donnadieu Institut Cochin INSERM U1016 Université Paris Descartes Paris, France
ISSN 2196-5501 ISSN 2196-551X (electronic) Resistance to Targeted Anti-Cancer Therapeutics ISBN 978-3-319-42221-3 ISBN 978-3-319-42223-7 (eBook) DOI 10.1007/978-3-319-42223-7 Library of Congress Control Number: 2016949129 © Springer International Publishing Switzerland 2016 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG Switzerland
Preface
After years of disappointments, cancer immunotherapy has finally gained considerable attention due to the development and use of approaches that target T cells, key players in the battle against cancer. In particular, immune checkpoint-targeting antibodies and adoptive T-cell therapies are starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. A major challenge now is to identify underlying mechanisms responsible for resistance to cancer immunotherapy in order to overcome them and propose more efficient strategies. For an effective direct destruction of cancer cells, CD8 T cells must fulfill several functions. First, they should be able to migrate efficiently into and within tumors in order to make contact with malignant cells. Second, they should be able to respond adequately to tumor antigens by releasing cytotoxic granules. In cancer patients, accumulating evidence suggests that responsiveness to tumor antigens is altered and current immunotherapies mainly a
Data Loading...
